KIRKLAND, Wash., March 14, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that the underwriters of Kestra’s initial public offering exercised in full their previously disclosed over-allotment option and have purchased 1,782,352 shares of common stock at a public offering price of $17.00 per share. After giving effect to the sale of over-allotment option, the total number of shares sold by Kestra in the initial public offering was 13,664,704 and the total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kestra, were approximately $232 million. The issuance and sale of the over-allotment option closed today. BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners and Wolfe | Nomura Alliance acted as co-manager for the offering. A registration statement relating to the common shares sold in this offering was filed with the Securities and Exchange Commission and became effective on March 5, 2025. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile at 212-902-9316, by email at Prospectus-ny@ny.email.gs.com, or by calling 1-866-471-2526; or Piper Sandler, by email at prospectus@psc.com, or by calling (800) 747-3924. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. Disclaimer “Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura and Wolfe Research Securities are serving as underwriters in the offering described herein. In addition, Wolfe Research Securities may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with the offering. CONTACT: Investor Contact

Neil Bhalodkar
neil.bhalodkar@kestramedical.com

KIRKLAND, Wash., Feb. 26, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, today announced the launch of its initial public offering of 10,000,000 common shares. In addition, the underwriters will have a 30-day over-allotment option to purchase up to 1,500,000 additional common shares from Kestra at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $14.00 and $16.00 per common share. Kestra has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol “KMTS.” BofA Securities, Goldman Sachs and Piper Sandler are acting as lead bookrunners for the proposed offering. Wells Fargo Securities and Stifel are acting as bookrunners and Wolfe | Nomura Alliance is acting as co-manager for the proposed offering. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; Goldman Sachs, by email at prospectus-ny@ny.email.gs.com, or by phone number at (866) 471-2526; or Piper Sandler, by email at prospectus@psc.com, or by phone number at (800) 747-3924. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. Disclaimer “Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura and Wolfe Research Securities are serving as underwriters in the offering described herein. In addition, Wolfe Research Securities may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with the offering. Investor Contact Marissa Bych or Webb CampbellGilmartin Groupinvestor.relations@kestramedical.com

KIRKLAND, Wash., Feb. 18, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that Al Ford is joining the company as Chief Commercial Officer (CCO). Mr. Ford will be responsible for advancing sales strategies and leading the Kestra commercial team. “We are pleased to welcome Al to the team,” said Brian Webster, President and Chief Executive Officer at Kestra. “With significant experience managing strategic sales and commercial operations, he brings valuable knowledge, perspective, and leadership to our organization. Al also has deep experience in the underlying defibrillation technologies that are central to the ASSURE® system. We are confident that he will be an impactful addition as we continue to drive adoption of our lifesaving system.” Mr. Ford brings 20 years of experience in MedTech organizations to his new role at Kestra. Most recently, he served as Chief Commercial Officer at Axonics where he led the development and execution of their commercialization strategy. Prior to that, he was Chief Commercial Officer at Cardiac Science Corporation. “I am honored to join Kestra in a commercial leadership role that aligns seamlessly with my experience,” said Mr. Ford. “The innovative Cardiac Recovery System® portfolio, and its ability to positively impact the lives of a meaningfully underserved patient population, were significant factors in my decision to join Kestra. I look forward to working with the team to execute on our commitment to patients and their prescribers.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and connected. Kestra was founded in 2014 by leaders from the external (AED) and implantable (ICD) defibrillation industries. For more information, visit www.kestramedical.com. INVESTOR CONTACTMarissa Bych or Webb CampbellGilmartin Groupinvestor.relations@kestramedical.com MEDIA CONTACTRhiannon PickusKestra Medical Technologies, Inc.Rhiannon.Pickus@kestramedical.com

July 24, 2024 08:00 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its […]